GlassScriptPhysician profile
Kimberly S Harmon
NPI 1831226950
$12,667.68
in general payments reported to CMS, 2019-2025
36 companies · $2,894 in 2025
The $2,894 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $302 · 2021: $1,191 · 2022: $2,081 · 2023: $2,063 · 2024: $2,735 · 2025: $2,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,682 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,681.80 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,943.90 | 2019-2025 | |
| Janssen Biotech, INC. | $1,807.97 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,180.70 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $996.02 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.66 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Gilead Sciences, INC. | $827.56 | 2019-2025 | |
| Ardelyx, INC. | $609.13 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $511.54 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $435.90 | 2019-2025 | Sucraid |
| Madrigal Pharmaceuticals | $407.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $401.76 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $384.38 | 2024-2025 | Zenpep |
| Celgene Corporation | $319.01 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $257.82 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $232.11 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $221.04 | 2021-2023 | |
| Pfizer INC. | $195.34 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $179.75 | 2019-2024 | Linzess |
| Lilly USA, LLC | $174.22 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $131.29 | 2022 | |
| Amgen INC. | $119.75 | 2021-2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $82.41 | 2025 | Iqirvo |
| Heidelberg Engineering, INC. | $66.33 | 2019 | |
| Merck Sharp & Dohme LLC | $53.29 | 2019-2024 | Dificid |
| Organon LLC | $45.26 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $36.88 | 2023-2024 | Rebyota |
| Daiichi Sankyo INC. | $27.61 | 2022-2024 | Injectafer |
| Ucb, INC. | $26.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.26 | 2024 | Cyltezo |
| Conmed Corporation | $19.44 | 2019 | |
| Redhill Biopharma INC. | $17.05 | 2022 | |
| Welch Allyn | $16.90 | 2021 | |
| Celltrion USA INC. | $16.39 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $15.93 | 2025 | Givlaari |
| Baxter Healthcare | $12.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.